

Edgar Filing: BIOENVISION INC - Form 8-K

BIOENVISION INC
Form 8-K
June 24, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 24, 2002

BIOENVISION, INC.
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of
Incorporation)

000-24875
(Commission File Number)

13-4
(IRS Employer Id

One Rockefeller Plaza, Suite 1600, New York, New York 10020
(Address of Principal Executive Offices) (ZIP Code)

Registrant's telephone number, including area code: (212) 445-6582

Not Applicable
(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

The Registrant is filing the attached material contracts as exhibits.

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(a) and (b) Not Applicable

(c) Exhibit. The following exhibits are filed with this report:

10.22 Exclusive License Agreement by and between Baxter
Healthcare Corporation, acting through its Edwards

Edgar Filing: BIOENVISION INC - Form 8-K

Critical-Care Division, and Implemed, dated as of May 6, 1997

- 10.23 License Agreement by and between Oklahoma Medical Research Foundation and Bridge Therapeutic Products, Inc., dated as of January 1, 1998
- 10.23(a) Amendment No. 1 to License Agreement by and among Oklahoma Medical Research Foundation, Bioenvision, Inc. and Pathagon, Inc., dated May 7, 2002
- 10.24 Inter-Institutional Agreement between Sloan-Kettering Institute for Cancer Research and Southern Research Institute, dated as of August 31, 1998
- 10.25 License Agreement between University College London and Bioenvision, Inc., dated March 1, 1999
- 10.26 Research Agreement between Stegram Pharmaceuticals Ltd., Queen Mary and Westfield College and Bioenvision, Inc., dated June 8, 1999
- 10.27 Research and License Agreement between Bioenvision, Inc., Velindre NHS Trust and University College Cardiff Consultants, dated as of January 9, 2001
- 10.28 Co-Development Agreement between Bioenvision, Inc. and Ilex Oncology, Inc., dated March 9, 2001

[Signature on following page.]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOENVISION, INC.

By: /s/ Christopher B. Wood

Christopher B. Wood
Chief Executive Officer

Date: June 21, 2002

EXHIBIT INDEX

Exhibit	Description
10.22	Exclusive License Agreement by and between Baxter Healthcare Corporation, acting through its Edwards Critical-Care Division, and Implemed, dated as of May 6, 1997
10.23	License Agreement by and between Oklahoma Medical Research

Edgar Filing: BIOENVISION INC - Form 8-K

Foundation and Bridge Therapeutic Products, Inc., dated as of January 1, 1998

- 10.23(a) Amendment No. 1 to License Agreement by and among Oklahoma Medical Research Foundation, Bioenvision, Inc. and Pathagon, Inc., dated May 7, 2002
- 10.24 Inter-Institutional Agreement between Sloan-Kettering Institute for Cancer Research and Southern Research Institute, dated as of August 31, 1998
- 10.25 License Agreement between University College London and Bioenvision, Inc., dated March 1, 1999
- 10.26 Research Agreement between Stegram Pharmaceuticals Ltd., Queen Mary and Westfield College and Bioenvision, Inc., dated June 8, 1999
- 10.27 Research and License Agreement between Bioenvision, Inc., Velindre NHS Trust and University College Cardiff Consultants, dated as of January 9, 2001
- 10.28 Co-Development Agreement between Bioenvision, Inc. and Ilex Oncology, Inc., dated March 9, 2001